Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program

Francesca Maines, Gaetano Facchini, Roberto Sabbatini, Donatello Gasparro, Umberto Basso, Claudia Mosillo, Enrico Campadelli, Francesco Massari, Teodoro Sava, Suzana Sirotova, Caterina Messina, Sarah Scagliarini, Sabrina Rossetti, Antonello Veccia, Stefania Kinspergher, Orazio Caffo

Research output: Contribution to journalArticle

Abstract

Aim: To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results. Patients & methods: Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14.8% had received both. Results: Median progression-free survival and overall survival were 4.8 and 13.1 months, respectively. A prostate-specific antigen reduction ≥50% was observed in 49.1%. Total 32.7% abiraterone-pretreated patients achieved a biochemical response compared with 56% of abiraterone-naive patients. Conclusion: Enzalutamide was safe and well tolerated. Its antitumor activity in abiraterone-pretreated patients was limited.
Original languageEnglish
Pages (from-to)2691-2699
Number of pages9
JournalFuture Oncology
Volume14
Issue number26
DOIs
Publication statusPublished - Nov 1 2018

Keywords

  • efficacy, enzalutamide, prostate cancer, safety

Fingerprint Dive into the research topics of 'Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program'. Together they form a unique fingerprint.

  • Cite this

    Maines, F., Facchini, G., Sabbatini, R., Gasparro, D., Basso, U., Mosillo, C., Campadelli, E., Massari, F., Sava, T., Sirotova, S., Messina, C., Scagliarini, S., Rossetti, S., Veccia, A., Kinspergher, S., & Caffo, O. (2018). Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: The Italian Named Patient Program. Future Oncology, 14(26), 2691-2699. https://doi.org/10.2217/fon-2018-0113